Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340625 · ClinicalTrials.gov registry record · Phase 1
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
A Phase 1 study of Bioequivalence, sponsored by Teva Pharmaceuticals U.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01340625 is a Phase 1 study of Bioequivalence that has completed, run by Teva Pharmaceuticals U. The registered enrollment target is 36 participants, below the 60-participant average among 3 other Bioequivalence trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01340625, a Phase 1 study of Bioequivalence, has completed, sponsored by Teva Pharmaceuticals U.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a single oral dose (2 \* 0.4 mg/35 mcg chewable tablets) in healthy female adult volunteers administered under fasting conditions.
Conditions Studied
Interventions
- DRUG Norethindrone/Ethinyl Estradiol
- DRUG Ovcon® 35 Fe
Study Locations (1)
North Dakota
- PRACS Institute, Ltd. - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340625
The ClinicalTrials.gov registry entry for NCT01340625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 3 other Bioequivalence trials with a reported enrollment target (40% lower). The listed sponsor is Teva Pharmaceuticals U, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioequivalence appearing as the primary indexed condition, and to 2 interventions - of which Norethindrone/Ethinyl Estradiol is the first listed.
NCT01340625 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.
Frequently Asked Questions
What is clinical trial NCT01340625 about?
NCT01340625 is a clinical study titled "Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions". This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a sing...
What is the current status of trial NCT01340625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-12. Estimated completion is 2007-01.
What conditions does trial NCT01340625 study?
This clinical trial studies the following conditions: Bioequivalence.
What interventions are being tested in trial NCT01340625?
The interventions under investigation include: Norethindrone/Ethinyl Estradiol (DRUG), Ovcon® 35 Fe (DRUG).
Who is sponsoring clinical trial NCT01340625?
This trial is sponsored by Teva Pharmaceuticals U, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01340625 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioequivalence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.
COMPLETED · Phase 1
-
A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.